Despite this limitation, our study provides important insights into the independent and synergistic effects of TP53mut and PI3K/AKT pathway alterations on survival across different BC subtypes, supporting genomic-guided treatment de-escalation or escalation strategies in BC, in particular, in early-stage hormone receptor+ subtype. The gene discussed is NR4A1; the disease is breast cancer.